CUBE TECH FAIR 2017: Experience the 4th Industrial Revolution

10 - 12 May 2017, Berlin, Germany.
The new annual CUBE TECH FAIR will showcase the pioneering and disruptive innovations and technologies that the top team of connectors and partners have hand picked globally. Interact with B2B startups, corporate executives, institutions and thought leaders that have been enabled by CUBE throughout the year.

CUBE TECH FAIR gives you fast and direct access to the most relevant B2B startup for your business:

  • Get premier access to B2B startups and more than 500 CEOs from B2B startups of all sizes and industries.
  • Experience and access innovations and disruptive technologies as well as outstanding projects.
  • Get connected to expertise and knowledge across different industries from digital health to manufacturing.

Hello Startups! Ready to boost your business?
Want to show the most relevant executives what you've got and engage in partnerships that help you scale up fast? Be part of the CUBE TECH FAIR 2017 in Berlin:

  • Meet 2,000+ business leaders, entrepreneurs, executives, investors, technology influencers, startup ecosystem leaders, institutions, and other brilliant minds.
  • Get premiere access to the industry and to their distribution channels. Show them how you can revolutionize the industry 4.0.
  • Opportunity for scaling up fast and short time to market through partnership with corporates.
  • Get globally connected to corporate expertise and knowledge across different industries from digital health to manufacturing.

Brilliant minds get their ticket now.

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

Hint: The faster you buy your ticket, the cheaper it is.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche purchases shares in tender offer for Ignyta…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares v...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]